Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GALR3 | O60755 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13909523 | 0.80 | MAPT (0.36) | MAPTALDH1A1SMN1; SMN2GALR3KMT2A | |
| SCHEMBL18263940 | 0.80 | GALR3 (0.31) | GALR3KMT2A | |
| SCHEMBL8953652 | 0.79 | MAPT (0.45) | MAPTALDH1A1MDM2SMN1; SMN2GALR3 | |
| SCHEMBL5030585 | 0.77 | MAPT (0.37) | MAPTALDH1A1GALR3GAAL3MBTL1 | |
| SCHEMBL11405724 | 0.77 | KMT2A (0.38) | MAPTALDH1A1MDM2SMN1; SMN2GALR3 | |
| SCHEMBL3641126 | 0.77 | GALR3 (0.39) | MAPTALDH1A1SMN1; SMN2GALR3GAA | |
| SCHEMBL4304025 | 0.77 | SMN1; SMN2 (0.36) | MAPTALDH1A1MDM2SMN1; SMN2GALR3 | |
| SCHEMBL3676705 | 0.77 | MAPT (0.38) | MAPTALDH1A1SMN1; SMN2GALR3KMT2A | |
| SCHEMBL22375160 | 0.77 | GAA (0.46) | MAPTALDH1A1MDM2SMN1; SMN2GAA | |
| SCHEMBL11431900 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8852757-B2 | Organic electroluminescence element, lighting device and display device | KONICA MINOLTA HOLDINGS, INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8129544-B2 | Preparation of 4-nitroimidazoles that are 2-substituted with a halo or optionally oxidized phenylthio group and 1-substituted with hydrogen, an oxiranylmethyl-, or a phenyl- group; dehalogenation, reduction, nitration, rearrangement | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20110006670-A1 | ORGANIC ELECTROLUMINESCENCE ELEMENT, NEW COMPOUND FOR THE SAME, DISPLAY DEVICE AND LIGHTING DEVICE USING THE SAME | KONICA MINOLTA HOLDINGS, INC. (JP) | 2011-01-13 | — | — | US | disclosed |
| US-7807843-B2 | 1-substituted-4-nitroimidazole compound and method for preparing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-10-05 | — | — | US | disclosed |
| US-20100045171-A1 | ORGANIC ELECTROLUMINESCENCE ELEMENT, LIGHTING DEVICE AND DISPLAY DEVICE | KONICA MINOLTA HOLDINGS, INC. (JP) | 2010-02-25 | — | — | US | disclosed |
| US-7569702-B2 | Method for producing 4-nitroimidazole compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-08-04 | — | — | US | disclosed |
| US-20080200689-A1 | 1-Substituted-4-nitroimidazole compound and method for preparing the same | OTSUKA PHARMACEUTICAL CO., LTD. | 2008-08-21 | — | — | US | disclosed |
| US-7368579-B2 | 1-substituted-4-nitroimidazole compound and process for producing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-05-06 | — | — | US | disclosed |
| US-20080097107-A1 | 1-substituted-4-nitroimidazole compound and method for preparing the same | OTSUKA PHARMACEUTICAL CO. LTD. | 2008-04-24 | — | — | US | disclosed |
| US-20070161802-A1 | Method for producing 4-nitroimidazole compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200689-A1 | 1-Substituted-4-nitroimidazole compound and method for preparing the same | CBR1, CBR3, DCXR | MAPT 3906/4885ALDH1A1 836/4885MDM2 3556/4885 |
| US-20070161802-A1 | Method for producing 4-nitroimidazole compound | COX4I1, GTF3C5, CYP4X1 | MAPT 4488/4885ALDH1A1 953/4885MDM2 1329/4885 |
| US-20110006670-A1 | ORGANIC ELECTROLUMINESCENCE ELEMENT, NEW COMPOUND FOR THE SAME, DISPLAY DEVICE AND LIGHTING DEVICE USING THE SAME | AOC2, AOC3, CDYL | MAPT 4583/4885ALDH1A1 54/4885MDM2 4290/4885 |
| US-20080097107-A1 | 1-substituted-4-nitroimidazole compound and method for preparing the same | CBR1, CBR3, DCXR | MAPT 3906/4885ALDH1A1 836/4885MDM2 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.